Soma Pharmacy Blognews

Antidepressants Linked to Newborn Problems New research provides further evidence that links antidepressant use among pregnant mothers to problems for their newborns at birth.

Mediterranean Diet May Fight Depression A new study suggests people who follow a traditional Mediterranean diet, rich in foods like vegetables, fruits, nuts, whole grains, olive oil, and fish, may be less likely to develop depression.

Vaccine May Treat Cocaine Addiction A new vaccine may one day help people who are addicted to cocaine to curb their drug use and overcome their dependency.

Schools Cut Back on Unhealthy Snacks U.S. schools have cut back on certain “less nutritious” foods and drinks, and Mississippi and Tennessee are leading the way, the CDC reports.

Autism May Be More Common Than Thought About 1% of U.S. children, or about one in 91, may have autism or an autism spectrum disorder, according to two new national surveys.

Snoring Surgery Offers Lasting Relief A minimally invasive snoring treatment that shrinks the tissue of the soft palate offers lasting relief from snoring.

Parents Unaware of Risks of Tiny Batteries Tiny “button type” batteries found in everything from vibrating teethers to musical touch-and-learn baby books present big dangers to young children, but parents and doctors are sorely undereducated about the topic.

Sanofi-Aventis To Acquire Fovea Targets CombinatoRx-derived combination drug candidate, Prednisporin

AVI BioPharma receives $11.5M DTRA fund to develop AVI-7012 for treating Junin virus infection AVI BioPharma, Inc. a developer of RNA-based drugs, announced today that it has received expanded contract funding of approximately $11.5 million from the Defense Threat Reduction Agency’s (DTRA) Transformational Medical Technologies Initiative (TMTI) to support development of the Investigational New Drug [...]

Bristol-Myers Squibb and AstraZeneca receive marketing authorisation for ONGLYZA in Europe Bristol-Myers Squibb Company and AstraZeneca announced today that the European Commission has granted marketing authorisation for ONGLYZATM in the 27 countries of the European Union.